Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.
Will Novo Nordisk (NVO) Stock Recover To $145 Levels?
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock is down 15% over this period.
What Analysts Are Saying About Novo Nordisk Stock
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current average compared to the previous average price target of $159.00.
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.
Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and Wegovy, posted disappointing clinical trial data for its experimental obesity drug CagriSema.
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off on the stock.
Novo Nordisk Stock: A Rare Buying Opportunity
Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong revenue growth and
Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.
Stocks to Watch Monday: Honda, Nissan, Novo Nordisk, Eli Lilly
The Japanese c
Better Buy: Eli Lilly or Novo Nordisk?
In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO) and whether or not the dip is worth buying over Eli Lilly (NYSE: LLY). Watch the short video to learn more, consider subscribing,
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...
Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms
CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...
Why Novo Nordisk’s Stock Plunge Rattled Markets Today
Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets ...
Novo Nordisk shares rebound 8%: can European markets sustain the rally?
European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...